🟢 Nyxoah is trading 11.26% up in after-hours trading after ACCCESS study met primary endpoints

Nyxoah is trading $1.68 (+11.26%) after its ACCCESS U.S. pivotal study met primary efficacy and safety endpoints.

• Nyxoah announced the results on September 2, 2026, supporting potential Genio indication expansion; AHI responders reached 77.2% and ODI responders 87.7%.
• The announcement was released at 4:05 p.m. ET, immediately before regular-session close, making it the clear company-specific catalyst; there were zero device-related serious adverse events through 12 months.